By lung-function change category (based on relative change in FVC%)a | ||||||
---|---|---|---|---|---|---|
Stable [A] | Marginal [B] | Significant [C] | Relative effect measure (95 % CI) | |||
(N = 250) | (N = 98) | (N = 142) | [C] vs. [A] | [C] vs. [B] | [B] vs. [A] | |
12-Month IR per Patient | IRR | |||||
Rate of suspected AEx | 0.26 | 0.47 | 0.74 | 2.87 (1.71–4.82) | 1.58 (0.95–2.64) | 1.82 (1.02–3.23) |
12-Month Risk | OR | |||||
Risk of suspected AEx | 19.2 % | 37.1 % | 50.9 % | 4.37 (2.09–9.16) | 1.76 (0.81–3.80) | 2.49 (1.28–4.82) |
Risk of progression | 62.6 % | 76.2 % | 85.6 % | 3.56 (1.66–7.64) | 1.86 (0.81–4.26) | 1.92 (0.91–4.04) |
Mortalityb | Risk by 12 Months | HR | ||||
Death due to any cause | 6.4 % | 13.1 % | 28.0 % | 5.05 (2.75–9.27) | 1.85 (1.05–3.26) | 2.73 (1.51–4.94) |
Death due to IPF | 5.5 % | 10.3 % | 24.3 % | 6.23 (2.96–13.14) | 1.94 (1.01–3.70) | 3.22 (1.59–6.53) |
Death due to AEx | 5.0 % | 9.3 % | 13.1 % | 3.91 (1.56–9.84) | 1.22 (0.54–2.77) | 3.21 (1.41–7.30) |